Volume | 1,355,905 |
|
|||||
News | (1) | ||||||
Day High | 2.97 | Low High |
|||||
Day Low | 2.73 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Poseida Therapeutics Inc | PSTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.88 | 2.73 | 2.97 | 2.79 | 2.77 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
8,624 | 1,355,905 | US$ 2.85 | US$ 3,865,521 | - | 1.54 - 4.27 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:47:38 | formt | 100 | US$ 2.78 | USD |
Poseida Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
269.2M | 96.49M | - | 64.7M | -123.43M | -1.28 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Poseida Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSTX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.03 | 3.00 | 1.98 | 2.58 | 897,722 | 0.75 | 36.95% |
1 Month | 3.06 | 3.22 | 1.87 | 2.45 | 647,488 | -0.28 | -9.15% |
3 Months | 3.35 | 4.27 | 1.87 | 3.13 | 723,204 | -0.57 | -17.01% |
6 Months | 2.10 | 4.27 | 1.87 | 3.04 | 826,883 | 0.68 | 32.38% |
1 Year | 2.73 | 4.27 | 1.54 | 2.63 | 831,587 | 0.05 | 1.83% |
3 Years | 9.40 | 11.10 | 1.54 | 3.82 | 584,781 | -6.62 | -70.43% |
5 Years | 17.00 | 17.62 | 1.54 | 4.82 | 535,043 | -14.22 | -83.65% |
Poseida Therapeutics Description
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. |